Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • OPOS, Fullpower enter...

    OPOS, Fullpower enter partnership to create-The First 24/7 Opioid Compliance Solution

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-01-05T09:00:49+05:30  |  Updated On 5 Jan 2020 9:00 AM IST

    New Delhi: Fullpower Technologies, the sleep technology company and OPOS, the opioid optimization company” announced a partnership to create “The first 24/7 opioid compliance solution“. The solution combines Fullpower’s patented contactless biosensing polysomnography grade sleep monitoring and AI platform with OPOS opioid optimization, functional monitoring, and prescriber risk management.


    The opioid epidemic has revealed that these powerful pain medications have real risks. The more recent reductions in opioid prescribing have created new obstacles for patients who rely on these important treatments. Physicians are challenged with compliance across a wide range of new opioid prescribing guidelines from the CDC, state medical boards and recent changes in state laws across the country that define a new de facto standard of care for opioid use. The Fullpower OPOS solution ensures that physicians are able to meet the new standard of care and adhere to the guidelines based on information that reflects the 24/7 life experience of the patient non-invasively while protecting privacy and security.


    It is estimated that there are 116 million people suffering from chronic pain in the US and as many as 30 million patients receive long term opioid care (IOM, 2011). Chronic opioid therapy and the complexities of polypharmacy affect sleep, daily activities, and quality of life. Through 24/7 functional monitoring, physicians and their patients can gain insight into the efficacy, safety, and risks of long term opioid use to maximize a patient’s quality of life.


    “Patients in America deserve safe access to the best medical treatment of their pain while we pursue a cure. OPOS delivers what doctors want and patients need.” – William G Brose, MD, OPOS Chief Medical Officer, a 30-year innovator in chronic pain management and Founder Stanford University Pain Program.


    According to Dr Carl Noe, Professor in the Department of Pain Management and Anesthesiology at UT Southwestern Medical Center, Director of its Division of Pain Management and Medical Director of the Eugene McDermott Center for Pain Management, “This is a game-changer. Optimizing both medication and non-medical tools along a continuum of chronic pain care has always been the holy grail. This is the realm of truly individualized care for pain patients.”


    Justin Kromelow, CEO of OPOS said: “We considered all available PSG-Level technologies as well as big data and AI technology platforms. These are essential components of a 24/7 compliance system. Fullpower is the clear technology leader. Only Fullpower demonstrated proven technology at a scale that is able to help us address this large problem and improve many lives today. That is why OPOS partnered with Fullpower.”


    Fullpower CEO, Philippe Kahn said: “Leveraging AI-innovation and Fullpower’s Sleep technology leadership, OPOS and Fullpower are delivering life-changing experiences that help manage one of the most challenging epidemics of the 2020 decade.”


    Also Read: Sanofi, Biocorp enter partnership to fit SoloStar insulin pens with Mallya technology

    AI platformbiosensing polysomnographycompliance solutionFullpowerFullpower TechnologiesopioidOPOSsleep monitoring

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok